We Work for Health | Washington

01/16/2026

"Of the investors surveyed, 87% said federal price setting policies such as Most Favored Nation would reduce U.S. biotech investment."

is bad for American businesses: https://www.incubatecoalition.org/post/incubate-investor-survey-u-s-policy-will-decide-u-s-china-race-for-biotech-leadership

01/14/2026

"Politicians in both parties long complained about this foreign free-riding, which disproportionately shifts the burden of paying for drug research and development onto Americans. That was all they did: complain."

won't work for American industries:

President Trump is reshaping the global pharmaceutical market and proving his critics wrong in the process.

01/12/2026

"Europe's system of drug price controls comes with serious problems, including reduced innovation and access to new medicines. Importing price controls would be one of the biggest policy mistakes the U.S. government could make."

https://www.usnews.com/opinion/articles/2026-01-06/medicine-trump-administration-drug-cost

01/09/2026

"For the U.S. to keep this economic engine humming and ensure access to lifesaving treatments and cures for patients, forward-thinking public policy is essential."

Read about state-level efforts to remain competitive in the biopharma space: https://binje.com/op-ed-how-n-j-can-help-ensure-u-s-stays-ahead-of-china-in-medical-innovation/

01/07/2026

"Codifying into law -- and locking in sweeping government price controls -- would trigger shortages today and choke off the breakthroughs of tomorrow."

Instead, reform addresses middle men directly: https://www.realclearpolicy.com/articles/2025/12/13/dont_import_europes_failures_1153223.html

01/05/2026

"The ethical obligation of physicians to advocate for patient welfare is stymied by a system that prioritizes short-term financial gains at the expense of patient experience and access to care."

Congress: reform can't wait.

https://www.spokesman.com/stories/2025/dec/19/karen-ferguson-pharmacy-benefit-managers-overdue-f/

12/23/2025

Happy Holidays from the We Work for Health Washington team!

12/19/2025

Congress is now considering legislation to bring greater transparency and accountability to PBMs.

The House PBM Reform Act (HR 4317) and the Senate PBM Price Transparency and Accountability Act would change how PBMs are allowed to operate in Medicare: https://ncpa.org/newsroom/executive-update/2025/12/12/deck-halls-hope-pbm-reform-ncpa-executive-update-december-12

12/17/2025

"The evidence remains clear: the hepatitis B birth dose is safe and an essential component in helping children develop immunity against a serious, potentially lifelong disease."

We know vaccines work: https://www.aap.org/en/news-room/news-releases/aap/2025/statement-from-leading-medical-health-and-patient-advocacy-groups-on-cdc-vaccine-meeting/

12/16/2025

The Trump Administration laid out a plan to set maximum fair prices for the IPAY 2027 selected drugs, cautioning that such price controls could harm patients and reduce innovation.

We Work For Health responded:

November 26, 2025 (Washington, DC) We Work For Health Executive Director Dan Leonard issued the following statement in response to the administration’s announcement on the Maximum Fair Prices (MFP) for IPAY 2027 selected drugs: “We Work For Health has been sounding the alarm about the dangers of...

12/12/2025

The U.S. Senate Aging Committee recently held a hearing focused on a major concern: Competition from China as a vulnerability in U.S. drug supply chain.

The We Work for Health blog covers the issue:

Members of the Senate Special Committee on Aging convened last week to hear from witnesses on restoring trust in American-made medicines. The hearing highlighted urgent concerns about America’s reliance on foreign nations, particularly China, for critical drug ingredients and finished medications....

12/10/2025

We Work for Health's recent blog post highlights a striking indicator of the momentum of China’s biopharma sector: Biotech stocks in China are up 80% versus 20% in the U.S.

Learn more:

Chinese biotech stock is reportedly “booming” while outperforming its U.S. counterpart, delivering the latest data point in a worrisome trend for America’s patients, economy, and national security. According to a recent STAT article, while U.S. biotech stock is up 20% this year, China's is up ...